Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frederic Amant

Showing results (81-90 of 180) with videos related to

Pageof 18
Sort By:
Breast Care (Basel, Switzerland)|September 9, 2010
Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian TumorJoachim Van Keirsbilck, Ine Riphagen, Hans Struyven, et al.
Journal of Translational Medicine|June 25, 2014
Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlationsMutsa T Madondo, Sandra Tuyaerts, Brit B Turnbull, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in studyIgnace Vergote, Frederic Amant, Gülten Oskay-Oezcelik, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 19, 2019
FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter studyMarie Plante, Nienke van Trommel, Stephanie Lheureux, et al.
The Oncologist|June 26, 2024
High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancerLilian van Wagensveld, Tom Van Nyen, Daniela Annibali, et al.
BMC Cancer|January 24, 2008
Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluationOlivier Gevaert, Frank De Smet, Toon Van Gorp, et al.
Gynecologic Oncology|June 24, 2005
Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancerFrederic Amant, Isabelle Cadron, Luca Fuso, et al.
Gynecologic Oncology|June 16, 2004
Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcomaFrederic Amant, Katrien Schurmans, Edwin Steenkiste, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Reproduction rates after cytotoxic therapyBirgit Mispelaere, Evelyn Van de Werf, Thomas D'Hooghe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 24, 2012
Pelvic exenterations for gynecological malignancies: a study of 36 casesManpreet Kaur, Steven Joniau, André D'Hoore, et al.
Pageof 18

Showing results (81-90 of 180) with videos related to

Sort By:
Pageof 18
Breast Care (Basel, Switzerland)|September 9, 2010
Bilateral Mammary Tuberculosis Associated with a Borderline Ovarian TumorJoachim Van Keirsbilck, Ine Riphagen, Hans Struyven, et al.
Journal of Translational Medicine|June 25, 2014
Variability in CRP, regulatory T cells and effector T cells over time in gynaecological cancer patients: a study of potential oscillatory behaviour and correlationsMutsa T Madondo, Sandra Tuyaerts, Brit B Turnbull, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 4, 2009
Carboplatin and paclitaxel in combination with oral enzastaurin in advanced ovarian or primary peritoneal cancer: results from a safety lead-in studyIgnace Vergote, Frederic Amant, Gülten Oskay-Oezcelik, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 19, 2019
FIGO 2018 stage IB2 (2-4 cm) Cervical cancer treated with Neo-adjuvant chemotherapy followed by fertility Sparing Surgery (CONTESSA); Neo-Adjuvant Chemotherapy and Conservative Surgery in Cervical Cancer to Preserve Fertility (NEOCON-F). A PMHC, DGOG, GCIG/CCRN and multicenter studyMarie Plante, Nienke van Trommel, Stephanie Lheureux, et al.
The Oncologist|June 26, 2024
High expression of phosphoglycerate dehydrogenase predicts poor outcome in patients with high-grade serous ovarian cancerLilian van Wagensveld, Tom Van Nyen, Daniela Annibali, et al.
BMC Cancer|January 24, 2008
Expression profiling to predict the clinical behaviour of ovarian cancer fails independent evaluationOlivier Gevaert, Frank De Smet, Toon Van Gorp, et al.
Gynecologic Oncology|June 24, 2005
Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancerFrederic Amant, Isabelle Cadron, Luca Fuso, et al.
Gynecologic Oncology|June 16, 2004
Immunohistochemical determination of estrogen and progesterone receptor positivity in uterine adenosarcomaFrederic Amant, Katrien Schurmans, Edwin Steenkiste, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 19, 2009
Reproduction rates after cytotoxic therapyBirgit Mispelaere, Evelyn Van de Werf, Thomas D'Hooghe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 24, 2012
Pelvic exenterations for gynecological malignancies: a study of 36 casesManpreet Kaur, Steven Joniau, André D'Hoore, et al.
Pageof 18